ptc596
Small moleculeexperimental
Clinical trial activity
5 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
0
Phase 3
1
Phase 4
0
Earliest trial started Mar 1, 2015 (NCT02404480)
Timeline
Indications
Mechanism of action
- TubulinINHIBITOR
Tubulin inhibitor
- Tubulin beta-4B chain (TUBB4B) ↗
- Tubulin beta-1 chain (TUBB1) ↗
- Tubulin alpha-3C chain (TUBA3C) ↗
- Tubulin alpha-4A chain (TUBA4A) ↗
- Tubulin beta-3 chain (TUBB3) ↗
- Tubulin alpha-1A chain (TUBA1A) ↗
- Tubulin beta-4A chain (TUBB4A) ↗
- Tubulin beta-8 chain (TUBB8) ↗
- Tubulin beta chain (TUBB) ↗
- Tubulin alpha-1B chain (TUBA1B) ↗
- Tubulin alpha-1C chain (TUBA1C) ↗
- Tubulin alpha-3E chain (TUBA3E) ↗
- Tubulin beta-2A chain (TUBB2A) ↗
- Tubulin beta-2B chain (TUBB2B) ↗
- Tubulin beta-6 chain (TUBB6) ↗
Chemistry & pharmacology
Loading structure…
SMILES
Cc1nc2ccc(F)cc2n1-c1nc(N)c(F)c(Nc2ccc(C(F)(F)F)cc2)n1- Mol. weight
- 420.35 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4594353 ↗
Also known as
- ptc596
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05269355 | Phase 2/Phase 3 (Phase 3) | May 23, 2022 | PTC Therapeutics |
| NCT03761095 | Phase 1 | Mar 13, 2019 | Columbia University, PTC Therapeutics |
| NCT03605550 | Phase 1 | Aug 1, 2018 | PTC Therapeutics, University of Cincinnati |
| NCT03206645 | Phase 1 | Aug 15, 2017 | PTC Therapeutics, University of Oklahoma |
| NCT02404480 | Phase 1 | Mar 1, 2015 | PTC Therapeutics |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| PTC Therapeutics | For profit | 5 | 3 | 2 | 2015 |
| Columbia University | Academic/Hospital | 1 | 0 | 1 | 2019 |
| University of Cincinnati | Academic/Hospital | 1 | 1 | 1 | 2018 |
| University of Oklahoma | Academic/Hospital | 1 | 1 | 1 | 2017 |
4 organizations
Page 1 / 1